Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion
24.2.2021 18:00:00 EET | Business Wire | Press release
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/
VueLife® "HP" Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire)
T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients.
Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorporates an innovative, patented laminate film layer that allows increased CO2 and O2 exchange versus other monolayer bag designs, yet maintains the scalability and process flexibility offered by a closed bag system. The increased permeability associated with the “HP” laminate layer was specifically designed for culturing cells requiring higher rates of respiration, such as T cells.
“The development of this product was in direct response to the market need for a cost effective culture vessel that provides efficient cell expansion in a scalable, closed system,” said Benjamin Le Quere, General Manager for the Saint-Gobain Life Sciences Bioprocess Solutions business unit. “VueLife® “HP” is an exciting result of the marrying of our expertise in material science with our knowledge in cell culture.”
The entire family of VueLife® cell culture bags utilize a common FEP fluid-contact layer. FEP creates an ideal environment for cell growth due to its gas permeability and liquid impermeability, while being biologically and chemically inert.
ABOUT SAINT-GOBAIN LIFE SCIENCES
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.
Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain.
Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 70 countries with more than 180,000 employees worldwide. The Company had €42.6 billion in sales in 2019.
www.celltherapy.saint-gobain.com/products/cell-culture-processing-bags/vuelife-hp-series
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005014/en/
Contact information
Media Contact:
Katy Oroszi:
330-283-3536
Katy.Oroszi@saint-gobain.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 16:30:00 EEST | Press release
ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential challenges facing modern data systems, as AI reshapes the demands placed on all data-intensive workloads. “At ClickHouse, we are interested in finding new and inno
Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 16:30:00 EEST | Press release
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte
EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership3.8.2026 16:00:00 EEST | Press release
EuroTeleSites, one of Central and Eastern Europe's leading independent tower companies, today announced the results of its first year in partnership with Sitetracker, the leading global Asset Lifecycle Management platform. One year into the deployment, EuroTeleSites reports meaningful progress in its digital transformation, with measurable improvements in operational efficiency, cross-market transparency, and project coordination across its six-country footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727009809/en/ EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership Driving Efficiency in a Complex, High-Investment Environment EuroTeleSites invests approximately 25% of its revenue into capital expenditures in 2026, funding the construction and upgrade of tower infrastructure across Central and Eastern European markets. Managing this level of scale and complexity demands robust digital support
Visa to Acquire BioCatch3.8.2026 15:30:00 EEST | Press release
Visa (NYSE: V) today announced it has signed a definitive agreement to acquire BioCatch, a leading provider of behavioral-first, multi-signal fraud intelligence, from funds advised by Permira and other shareholders for $2.4 billion in cash. The acquisition of BioCatch complements Visa’s existing cyber, fraud, risk and security solutions and is expected to help clients better protect themselves and their customers from the growing threat of account takeovers, scams, money mules and application fraud. Since its inception, BioCatch has developed innovative AI and machine learning-based solutions that analyze thousands of application, behavioral, device, and network signals—such as keystrokes, touch gestures, and device handling—to detect fraud and distinguish legitimate users from fraudsters in real time. BioCatch protects 1.8 billion devices and 760 million users around the world, serving more than 350 banking clients in 21 different countries, including more than 100 of the largest bank
U.S. Bank Investment Services enhances investor and client onboarding experience for alternative investments3.8.2026 15:16:00 EEST | Press release
U.S. Bank Investment Services today announced it has gone live with a new client lifecycle management (CLM) platform, providing a comprehensive onboarding solution for alternative investment clients and the investors in their funds. The implementation is a key milestone in Investment Services’ multi-phased technology transformation strategy, aimed at modernizing processes, workflows and reporting across the private funds space. U.S. Bank leverages CLM provider Fenergo and its Fen-X platform. Fen-X automates many of the manual processes traditionally associated with underlying investors and direct client relationships and accelerates account setup while maintaining regulatory requirements. The enhanced onboarding experience provides investors and clients with more transparency throughout the process and enables integration with other solutions providers involved in the investor journey, such as screening and tax reporting. The investor experience has been further enhanced with an invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom